14 Apr 22 | CA | BIOJAMP announced the launch of SIMLANDI™/AVT02 (high-concentration, low volume, citrate-free biosimilar adalimumab) in Canada. JAMP Pharma has exclusive commercialisation rights to Alvotech’s AVT02 in Canada in accordance with their January 2020 agreement.
18 Apr 22 | Amgen released preliminary results from its Ph III study of ABP654 (proposed ustekinumab biosimilar) in adults with severe plaque psoriasis. Amgen reported that the study met the primary efficacy endpoint, and that the safety profile of ABP654 was comparable to STELARA®.
20 Apr 22 | Biogen reported that it has completed the sale of its stake in the Samsung Bioepis joint venture to Samsung Biologics. In January 2022 Biogen announced that it would sell its stake in Samsung Bioepis for an aggregate consideration of up to USD $2.3 billion.
21 Apr 22 | The results of Alexion’s Ph II studies of cetuximab and nivolumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) were published in Clinical Cancer Research. The researchers reported that the combination of cetuximab and nivolumab is effective in patients with both previously treated and untreated R/M HNSCC.
Pearce IP offers Australian based, generics and biosimilars focused lawyers, attorneys and regulatory affairs experts, with incomparable global experience, technical competence, and commercial elegance. Call us today on 02 9023 9988 or email info@pearceIP.law.